Palatin Technologies (PTN) Other Operating Expenses (2012 - 2025)
Palatin Technologies' (PTN) quarterly Other Operating Expenses came in at -$2.3 million in Q2 2025, down 114.97% YoY from $15.6 million in Q2 2024, and down 193.28% on a QoQ basis from $2.5 million in Q4 2024.
Palatin Technologies (PTN) Other Operating Expenses (2012 - 2025) Analysis & Trends
Palatin Technologies (PTN) has 13 years of Other Operating Expenses data on file, last reported at -$2.3 million in Q2 2025.
- Quarterly Other Operating Expenses fell 114.97% year-over-year to -$2.3 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$2.3 million (down 112.9% YoY) and the FY2025 annual result came in at -$5.2 million, down 167.44% from the prior year.
- Other Operating Expenses retreated to -$2.3 million in Q2 2025, from $2.5 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $15.6 million in Q2 2024 to a low of -$7.8 million in Q4 2023.
- A 5-year average of $518350.4 and a median of $25202.0 in 2024 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2024 — Other Operating Expenses soared 131.96% — and 2025, when it slumped 114.97%.
- Tracing PTN's Other Operating Expenses over 5 years: stood at -$4.4 million in 2021, then soared by 101.96% to $86496.0 in 2022, then plunged by 9144.91% to -$7.8 million in 2023, then soared by 131.96% to $2.5 million in 2024, then plunged by 193.28% to -$2.3 million in 2025.
- The last three Other Operating Expenses figures came in at -$2.3 million (Q2 2025), $2.5 million (Q4 2024), and $15.6 million (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -2.33 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Jun 30, 2024 | 15.58 Mn |
| Mar 31, 2024 | 25,202.00 |
| Dec 31, 2023 | -7.82 Mn |
| Sep 30, 2022 | 86,496.00 |
| Jun 30, 2021 | -4.41 Mn |
| Sep 30, 2020 | 1.62 Mn |
| Jun 30, 2019 | 116.00 |
| Mar 31, 2019 | 222.00 |
| Dec 31, 2018 | -221.00 |
| Sep 30, 2018 | -273.00 |
| Jun 30, 2018 | -8.34 Mn |
| Mar 31, 2018 | -9.47 Mn |
| Dec 31, 2017 | -7.66 Mn |
| Sep 30, 2017 | -15.69 Mn |
| Jun 30, 2017 | -5.48 Mn |
| Mar 31, 2017 | -13.82 Mn |
| Dec 31, 2016 | -9.43 Mn |
| Sep 30, 2016 | -12.42 Mn |